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PCardiac Transplantation
Use of Cardiac Allografts With Mild and
Moderate Left Ventricular Hypertrophy Can Be Safely
Used in Heart Transplantation to Expand the Donor Pool
Sorel Goland, MD,‡ Lawrence S. C. Czer, MD,* Robert M. Kass, MD,† Robert J. Siegel, MD,*
James Mirocha, MS,† Michele A. De Robertis, RN,† Jason Lee, BS,† Sharo Raissi, MD,†
Wen Cheng, MD,† Gregory Fontana, MD,† Alfredo Trento, MD†
Los Angeles, California; and Rehovot, Israel
Objectives The purpose of this study was to evaluate outcomes of heart transplantation (HTx) and changes in left ventricu-
lar wall thickness (LVWT) post-HTx using donors with left ventricular hypertrophy (LVH).
Background Limited data are available on use of donor hearts with LVH in HTx.
Methods We reviewed 427 patients who underwent HTx: 62 received hearts with LVH (interventricular septum [IVS] or
posterior wall [PW] thickness 1.2 cm) by echocardiography, and 365 received hearts without LVH. The median
follow-up was 3.8 years (range 0 to 16.2 years).
Results Recipient age was 56  11 years and donor age was 30  12 years. Baseline recipient characteristics were
similar in both groups. Donors with LVH were older (35  12 years vs. 29  12 years, p  0.001) and had
higher rates of intracranial hemorrhage (38% vs. 15%, p  0.001). The LVWT was increased in the LVH group
compared with LVWT in the non-LVH group (IVS: 1.28  0.18 cm vs. 0.85  0.19 cm, PW: 1.27  0.19 cm vs.
0.85  0.20 cm, p  0.0001 for both groups). Mild LVH (1.2 to 1.3 cm) was found in 42%, moderate (1.3 to
1.7 cm) in 53%, and severe (1.7 cm) in 5% of donors with LVH. Left ventricular wall thickness regression oc-
curred in both IVS and PW (1.28  0.18 cm vs. 1.10  0.13 cm vs. 1.13  0.14 cm, and 1.27  0.19 cm vs.
1.11  0.11 cm vs. 1.13  0.14 cm, at baseline, 1 year, and 5 years, respectively; p  0.001 for change from
baseline to 1 and 5 years for both locations). Patients with or without donor LVH had similar 1-year (3.5% vs.
9.5%, p  0.2) and 5-year survival rates (84  5.9% vs. 70  2.7%, p  0.07).
Conclusions Short- and long-term survival rates and rates of LVH at follow-up were similar in both groups, suggesting that
donor hearts with mild and moderate LVH can be safely used in HTx. (J Am Coll Cardiol 2008;51:1214–20)
© 2008 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.11.052a
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Ceart transplantation (HTx) provides definitive therapy for
atients with end-stage congestive heart failure. Although
mproved preservation techniques and post-HTx immuno-
uppression have significantly improved outcomes, the
umber of patients on waiting lists has progressively in-
reased over the last decade (1–3). Although initially strict
onor and recipient selection criteria were established,
iberalization of donor selection criteria and ways of expand-
ng the donor pool have been suggested (4–7). Use of donor
earts with left ventricular hypertrophy (LVH) has varied
rom the *Division of Cardiology and †Department of Cardiothoracic Surgery,
edars-Sinai Medical Center, Los Angeles, California; and the ‡Division of
ardiology, Kaplan Medical Center, Rehovot, Israel. Supported in part by a grant
rom the Rav-Noy Foundation and the Save-A-Heart Foundation, Cedars-Sinai
edical Center, Los Angeles, California.y
Manuscript received July 12, 2007; revised manuscript received October 26, 2007,
ccepted November 12, 2007.mong transplant centers, and there is little information
oncerning transplantation of donor hearts with LVH.
Until recently, only 2 small studies have been published
nd found that the presence of LVH in the donor heart was
ssociated with early graft dysfunction and lower survival
8,9). Moreover, there are no data regarding the changes in
easured wall thickness after HTx in this patient popula-
ion. Given that use of donor hearts with LVH may permit
n expansion of the donor pool, we aimed to review our
xperience with HTx using donors with LVH and to
valuate the changes in LVH over time.
ethods
atients. We retrospectively reviewed 427 consecutive
Tx donors and recipients between 1989 and 2004 at
edars-Sinai Medical Center. Recipients younger than 16ears of age and those with combined heart-lung transplan-
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March 25, 2008:1214–20 Heart Transplantation of Donors With LVHation were excluded. The donor and recipient evaluation
nd rejection surveillance have been described elsewhere
10). The post-HTx regimen included induction therapy
onsisting of OKT3 or Thymoglobulin. Maintenance immu-
osuppressive therapy included cyclosporine or tacrolimus,
zathioprine or mycophenolate mofetil, and prednisone.
Donor hearts were preserved using a cold infusion of
niversity of Wisconsin solution or Stanford solution prior
o 2000. HTx was performed using the total orthotopic
bicaval) technique in 85% of recipients.
efinition and grading of LVH. Left ventricular hyper-
rophy was quantitatively assessed by echocardiography
sing wall-thickness measurements according to American
ociety of Echocardiography recommendations (11). Left
entricular hypertrophy was defined as interventricular sep-
um (IVS) and/or posterior wall (PW) thickness 1.2 cm.
ild LVH was defined as wall thickness of 1.2 to 1.3 cm,
oderate LVH as 1.4 to 1.7 cm, and severe LVH as 1.7
m. Follow-up echocardiograms at 1 and 5 years post-HTx
ere available in 66% and 49% of patients, respectively.
he electrocardiogram (ECG) definition of LVH was
ased on standard voltage criteria: SV1  RV5 or RV6
35 mm.
tatistical analysis. Results for continuous variables are
resented as mean  SD and for categorical variables as
requency (percentage). The comparison of continuous vari-
bles between groups was made using t test or the Wilcoxon
ank sum test as appropriate. Categorical variables were
ompared using chi-square or Fisher exact tests. Within-
roup change in numerical variables across 2 time points
as assessed by the Wilcoxon signed rank test. Within-
roup change in dichotomous variables across 2 time points
as assessed by the McNemar test for related proportions.
urvival estimates were generated by the Kaplan-Meier
ethod. The log-rank and Wilcoxon tests were used to
ompare survival across groups. Multivariable stepwise Cox
roportional hazards models were employed to assess vari-
bles associated with the risk of death. All statistical tests
ere two-sided, and a significance level of 0.05 was used
hroughout. Statistical analyses were performed using the SAS
ystem version 9.1 (SAS Institute Inc., Cary, North Carolina).
esults
onor and patient characteristics. Sixty-two patients re-
eived a donor heart with LVH, and 365 received a heart
ithout LVH. Median follow-up was 3.8 years (range 0 to
6.2 years).
Donors with LVH were significantly younger (p 
.0003) and had a higher prevalence of intracranial bleeding
p  0.02) (Table 1). No significant differences were
bserved in terms of other baseline characteristics. Twenty-
ine donors (48%) had history of hypertension (HTN).
mong donors with LVH, 42% of patients had mild, 53%
ad moderate, and 5% had severe LVH as determined by (chocardiography. Twenty-five
40%) donors also had evidence
f LVH by as determined by
CG.
Baseline pre-HTx recipient
haracteristics were similar in the
groups and are presented in
able 1. The post-HTx recipient
haracteristics are presented in
able 2. A long (240 min)
schemic time was found only
mong patients who received al-
ografts without LVH (6%). A
arger number of patients with
onor LVH were treated with
acrolimus (p  0.004). No sig-
ificant differences were found in
erms of length of hospitaliza-
ion, acute cellular rejection
3A, and cytomegalovirus infection rates.
urvival analysis. No significant differences in 30-day and
-year mortality were found between recipients of donor
eart with LVH compared with those without LVH (1.6%
s. 3.3%, p  0.2, and 3.5% vs. 9.5%, p  0.7, respectively).
he overall survival of the 2 groups is shown in Figure 1 and
eveals no significant difference (p  0.07) (Fig. 1A).
ultivariable stepwise Cox proportional hazards analysis
ound evidence that donor LVH was associated with a
educed death hazard rate. The independent predictors of
ortality are shown in Table 3.
Prior studies have demonstrated lower survival in
ecipients of older donor hearts (12). We divided both
roups, with and without donor LVH, by donor age 45
ears (younger) and 45 years (older). Survival analysis
evealed a trend (p  0.08) (Fig. 1B) indicating a possible
ifference among recipients of younger donors with or
ithout donor LVH and older donors with or without LVH.
A separate analysis comparing survival among patients
ho received hearts with mild LVH or moderate or severe
VH did not reveal significant differences (p  0.82). No
ignificant difference in survival between recipients with
onor LVH as determined by both ECG and echocardiog-
aphy and those with donor LVH determined only by ECG
vidence was observed (p  0.58) (Fig. 2A). For about the
rst 2.5 years post-transplant, almost identical survival was
bserved among recipients of donor LVH with and without
onor history of HTN; however, those with donor history
f HTN have a trend for worse survival thereafter (p 
.05) (Fig. 2B).
One hundred sixty-two patients died over the follow-up
eriod: 13 patients (1 within 30 days) in the LVH group
nd 149 (12 within 30 days) of those in the group without
VH. The causes of late deaths were right ventricular
ailure (3%), rejection (10%), cardiac (36%), and noncardiac
Abbreviations
and Acronyms
ACEI  angiotensin-
converting enzyme inhibitor
ARB  angiotensin
receptor blocker
HTN  hypertension
HTx  heart
transplantation
IVS  interventricular
septum
LV  left ventricular
LVH  left ventricular
hypertrophy
LVWT  left ventricular
wall thickness
PW  posterior wall51%). Compared with recipients of allografts without
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Heart Transplantation of Donors With LVH March 25, 2008:1214–20VH, the vast majority of patients with LVH (11 or 92%
s. 64 or 47%) died from noncardiac causes after 30 days.
hanges in left ventricular thickness at 1- and 5-years’
ollow-ups. Figures 3A and 3B show the comparison of
VS and PW thickness measurements for patients with
Baseline Characteristics of Donors and Recipien
Table 1 Baseline Characteristics of Donors
Donors W
(n 
Donor characteristics
Age (yrs) 35.5 
Male gender 38
BSA (m2) 1.95 
Caucasian 32
Intracranial bleeding 24
Cerebrovascular accident 10
Inotropic support 56
Thyroxine treatment 18/61
IVS thickness (cm) 1.28 
PW thickness (cm) 1.27 
Mild LVH (WT 1.2 to 1.3 cm) 26
Moderate LVH (WT 1.3 to 1.7 cm) 33
Severe LVH (WT 1.7 cm) 3
Recipient characteristics
Age (yrs) 56.9 
Male gender 47
Caucasian 46
Diabetes mellitus 22
Hypertension 22
Creatinine (mg/dl) 1.52 
Ischemic cardiomyopathy 32
NYHA functional class III to IV 59
Ejection fraction (%) 21.6 
Inotropic support 38
High PVR (3 Wood units) 9
BSA (m2) 1.96 
Height donor/recipient ratio 1.00 
Weight donor/recipient ratio 1.03 
Ischemic time 240 min 0
Ischemic time (min) 161 
*The p value compares patients with donor LVH with donors without d
BSA  body surface area; IVS  interventricular septum; LVH 
pulmonary vascular resistance; PW  posterior wall; WT  wall thick
ost-Transplantation Recipient Characteristics
Table 2 Post-Transplantation Recipient Characteristics
Donors With LVH
(n  62)
Donors Without LVH
(n  365)
p
Value*
Hospitalization days 17.2 22.7 16.9  11.4 0.4
Tacrolimus/cyclosporine
treatment
0.004†
Tacrolimus treatment 25 (40%) 80 (22%)
Cyclosporine
treatment
37 (60%) 284 (78%)
Rejection  3A 4 (7%) 44 (13%) 0.2
Graft CAD 1 (2%) 24 (11%) 0.09
CMV infection 6 (10%) 55 (15%) 0.3
The p value compares patients with donor LVH with donors without donor LVH. †The p value is fors
oth tacrolimus and cyclosporine treatment.
CAD  coronary artery disease; CMV  cytomegalovirus; other abbreviations as in Table 1.onor LVH and those without LVH at baseline and at
ollow-up. Between the groups, significant differences in the
onor hearts’ wall thicknesses were found only at baseline.
t follow-ups (1 and 5 years), wall thickness was similar in
he 2 groups. Left ventricular (LV) thickness regression
ccurred in recipients of allografts with LVH at follow-up
Fig. 4A). Left ventricular wall thickness regression oc-
urred in both IVS (1.28  0.18 cm vs. 1.10  0.13 cm vs.
.13  0.14 cm, for baseline, 1 year, and 5 years; p  0.001
or change from baseline to 1 and 5 years) and PW (1.27 
.19 cm vs. 1.11  0.11 cm vs. 1.13  0.14 cm; p  0.001
or change from baseline to 1 and 5 years). Rates of
ost-transplant LVH (38% vs. 32%, p 0.5) were similar in
oth groups at follow-ups. Patients with or without donor
VH had similar 1-year (3.5% vs. 9.5%, p 0.2) and 5-year
84  5.9% vs. 70  2.7%, p  0.07) survival rates. Both
roups had a similar percentage of patients with LVH at 1
nd 5 years (Fig. 4B). Sixty-seven percent of the donor
VH group at 1 year and 63% at 5 years no longer met the
ecipients
VH Donors Without LVH
(n  365) p Value*
29.5  11.9 0.0003
) 261 (72%) 0.1
1.90  0.25 0.2
) 201 (55%) 0.7
) 56 (15%) 0.02
) 46 (13%) 0.4
) 338 (93%) 0.6
) 115/336 (34%) 0.6
0.85  0.19 0.0001
0.85  0.20 0.0001
)
)
56.2  11.4 0.7
) 299 (82%) 0.3
) 271 (74%) 0.9
) 84 (23%) 0.04
) 106 (29%) 0.3
1.39  0.77 0.1
) 190 (52%) 0.9
) 375 (94%) 0.9
22.2  9.6 0.55
) 208 (59%) 0.8
) 72 (21%) 0.4
1.93  0.23 0.3
1.00  0.07 0.8
10.1  0.26 0.6
22 (6%) 0.06
161  79 0.9
VH.
tricular hypertrophy; NYHA  New York Heart Association; PVR ts
and R
ith L
62)
12.0
(61%
0.22
(52%
(38%
(16%
(90%
(30%
0.18
0.19
(42%
(53%
(5%)
11.5
(75%
(74%
(36%
(36%
0.84
(52%
(94%
6.9
(61%
(16%
0.25
0.06
0.26
45
onor Ltudy’s criteria for LVH.
C
m
a
s
g

m
d
z
(
b
r
t
D
T
H
L
d
l
d
o
L
L
h
p
C
B
a
1217JACC Vol. 51, No. 12, 2008 Goland et al.
March 25, 2008:1214–20 Heart Transplantation of Donors With LVHomparison of blood pressures and antihypertensive
edications between recipients of allografts with LVH
nd without LVH. As presented in Figure 5A, similar
ystolic and diastolic blood pressures were observed in the 2
roups at 1 year and 62% of all patients had blood pressure
140/90 mm Hg. Antihypertensive post-HTx manage-
ent treatment is presented in Figure 5B. A similar
istribution of treatments using angiotensin-converting en-
yme inhibitors (ACEIs), angiotensin receptor blockers
Figure 1 Survival of Recipients of Donor Hearts
With LVH and Without LVH and by Donor Age
(A) Recipients of donor hearts with left ventricular hypertrophy (LVH) and those
without LVH had similar 30-day, 1-year, and 5-year survival rates. (B) Survival
analysis of recipients of donor hearts with LVH and without LVH stratified by
donor age revealed a trend for better survival among recipients of younger
donors’ hearts with LVH and without LVH compared with older donors’ hearts
with LVH and without LVH.
ox Proportional Hazards Survival Model
Table 3 Cox Proportional Hazards Survival Model
Variables Hazard Ratio 95% CI p Value
Older recipient age (55 yrs) 1.81 1.25–2.62 0.02
Race (African American) 1.86 1.15–3.02 0.02
BMI (27 kg/m2) 1.61 1.11–2.34 0.03
Donor LVH 0.49 0.26–0.92 0.04
UNOS status (2) 0.66 0.46–0.96 0.03d
MI  body mass index; CI  confidence interval; UNOS  United Network for Organ Sharing; other
bbreviations as in Table 1.ARBs), and/or calcium channel blockers were found in
oth groups. Overall, the vast majority (76%) of patients
eceived either single or combination drug management
reatments.
iscussion
his is the first study to evaluate the long-term outcomes of
Tx using donors with LVH and to assess the changes in
VWT over time. The main findings of this study are that
onor LVH did not have a negative influence on short- or
ong-term survival; the degree of LVH (mild to moderate)
id not affect the survival; both groups showed similar rates
f post-transplantation complications; and regression of
VH was obtained over time in recipients with donor
VH.
Donor availability remains the main limiting factor in
eart transplantation; as a result, approximately 2,000 trans-
lants are performed annually in the U.S. (1). There is little
Figure 2 Survival of Recipients of Donor Hearts With LVH by
Echo, Both Echo and ECG, or by Donor History of HTN
(A) Survival of recipients of donor hearts with left ventricular hypertrophy (LVH)
as determined by echocardiography (echo) alone did not differ from those
determined by both echo and electrocardiogram (ECG). (B) For approximately
the first 2.5 years post-transplant, almost identical survival was observed
among recipients of donor LVH with and without donor history of hypertension
(HTN); however, those with donor history of HTN have a trend for worse survival
thereafter. Summary tables (insets) provide survival estimates (SE) at 30
days, 1 year, and 5 years, respectively.ata regarding HTx of donor hearts with LVH (8,9).
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Heart Transplantation of Donors With LVH March 25, 2008:1214–20ecent recommendations by Zaroff et al. (6) discourage the
se of donors hearts with more than mild LVH when both
chocardiographic (13 mm) and ECG evidence of LVH
s present.
urvival and post-transplant complications. Until now
nly 2 small studies reported the short-term outcomes of
Tx recipients with donor LVH (8,9). Marelli et al. (8)
valuated outcomes of 37 patients with donor LVH, but in
heir study, direct measurements of wall thickness by echo-
ardiography were available for only 6 patients. Lower
-year survival has been found in those with donors having
 history of HTN, ischemic time 180 min, LVH indicated
y both ECG and echocardiography, and in recipients with
VH greater than mild or unknown. Aziz et al. (9) reported
0-day outcomes of 9 patients who received allografts with
VH (wall thickness 11 mm).This study demonstrated
hat the presence of donor LVH increased the incidence of
arly graft dysfunction (9). In contrast to these 2 reports, our
tudy has a significantly larger number of recipients with
onor LVH and importantly had a quantative assessment of
VWT. In addition, the median follow-up was much
onger (3.8 years, range 0 to 16.2 years). In contrast to
reviously published data (8,9), no significant differences in
0-day and 1-year mortality were found between patients
ho received allografts with LVH compared with those
ithout LVH. Of note, all recipients with donor LVH had
schemic time 240 min. Survival curves extending more
Figure 3 Comparison of LV IVS and PW Thicknesses in
Recipients of Donor Hearts With and Without LVH
(A) No significant differences of left ventricular (LV) interventricular septum
(IVS) wall thickness in recipients of donor hearts with and without left ventricu-
lar hypertrophy (LVH) were obtained at 1- and 5-year follow-ups. (B) At follow-
ups (1- and 5-year), wall thickness was similar in patients with donor LVH and
those without LVH. PW  posterior wall.han a decade showed no significant differences betweenecipients with and without donor LVH; moreover, a trend
oward better survival for those with LVH was observed.
ultivariable Cox regression analysis found that donor
VH was not associated with risk of death and even had
ome protective effect.
One-third of the donors with LVH had evidence of LVH
n both echocardiogram and ECG. Recipients of hearts
ith LVH determined by both measures did not show
igher mortality compared with patients with donor LVH
etermined by echocardiography alone, which contrasts
ith the previous report (8). However, donor LVH along
ith a history of HTN was found to have some negative
mpact on late post-HTx survival supporting the published
ata (8). Survival analysis revealed a trend that indicated a
ossible difference among recipients of younger donors
45 years) with or without donor LVH and older donors
ith or without LVH.
Patients who received hearts with mild LVH, moderate-
evere LVH, and no LVH had similar survival; however, the
umber of patients with severe donor LVH was too small to
ake any statement regarding this particular subset.
hanges in LVWT, LVH regression, and associated
actors. In this study, we found that LVWT at follow-ups
1 and 5 years) was similar in the 2 groups. Regression of
V thickness occurred in recipients of donors with LVH.
About one-third of all recipients of donors with and
ithout LVH had hypertrophy at follow-ups. Previous
Figure 4 LVWT After HTx With Donor LVH, and LVH
Prevalence With and Without Donor LVH After HTx
(A) Left ventricular wall thickness (LVWT) regression occurred in both interven-
tricular septum and posterior wall at 1- and 5-year follow-ups. The p value
refers to change from baseline to both 1- and 5-year follow-ups. (B) Recipients
of donor hearts with LVH and without LVH had a similar percentage of patients
with LVH at 1- and 5-year follow-ups. Abbreviations as in Figure 3.
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March 25, 2008:1214–20 Heart Transplantation of Donors With LVHtudies reported various incidence of post-transplantation
VH from very low 13% to surprisingly high 83% at 1 year
ased on LV mass criteria (13,14). Development of LVH in
he post-HTx heart involves multiple factors, including
TN and immune injury (12). Although HTN is common
fter HTx, occurring in 74% of recipients at 1 year accord-
ng to the International Society for Heart and Lung Trans-
lantation registry (12), highly variable prevalence of LVH
n this population may be related to different cutoff values of
V mass used for diagnosis of LVH (12,13,15).
Two-thirds of our entire cohort received treatment to
aintain blood pressures in the normal range (140/90
m Hg). As has been demonstrated previously, in the
eneral population with HTN as well in post-HTx patients,
hese antihypertensive drugs can prevent or even lead to
egression of LVH (16–21). Moreover, ACEI and/or ARB
herapy has been demonstrated to lead to a regression of
VH regardless of blood pressure control.
Thus, the favorable outcomes of recipients of donor
earts with LVH in our study can be explained by a number
f factors: 1) Although donors with LVH were on average
lder than those without LVH, they were still relatively
oung; therefore, it is less likely that they had long-standing
ypertension. 2) No patients had ischemic time longer than
40 min, the presence of which can affect the outcome in
Figure 5 BP at 1 Year Post-HTx, and After Treatment in
Recipients of Donor Hearts With and Without LVH
(A) Recipients of donor hearts with left ventricular hypertrophy (LVH) and with-
out LVH had similar systolic and diastolic blood pressures at 1-year post-trans-
plantation. (B) A similar distribution of treatment with ACEI and/or ARB and Ca
channel blockers was found among patients with donor LVH and without LVH.
ACEI  angiotensin converting enzyme inhibitor; ARB  angiotensin receptor
blocker; BP  blood pressure; Ca  calcium; HTx  heart transplantation.ptimal donors, but probably more so in those with LVH. m) On follow-up, a relatively low proportion of patients had
VH after surgery, which has a potentially negative effect
n late survival. 4) The aggressive treatment of HTN and
ide use of medications that have been shown to have a
eneficial effect on LV remodeling may play an important
ole in outcomes among recipients with donor LVH.
ractical implications. The main issue raised in this study
s whether all donors with LVH assessed by echocardiog-
aphy should be excluded from the potential donor pool.
he recent recommendations suggest use of only donors
ith mild LVH (1.3 cm). This was based on a small study
8) with short-term follow-up where quantitative assess-
ent of most patients was not available. In our study, we
ound good short- and long-term outcomes among recipi-
nts who received allografts with mild-to-moderate LVH
1.2 to 1.7 cm). Of note, our findings should not be
xtrapolated to longer ischemic times (240 min). In
ddition, the incidence of donor diabetes mellitus was very
ow and not always available; therefore, our results mostly
pply to nondiabetic donors with LVH. Although the
verall outcomes of patients with donor LVH are similar to
hose without LVH, recipients of younger donor hearts with
VH had the best survival rates, leading us to think that
ost of them had physiologic LVH. A history of donor
TN in those recipients with donor LVH was found to
ave an unfavorable impact on late survival, suggesting that
hose patients had more advanced changes in myocardial
tructure and diastolic function.
This last finding brings up the next important question:
ow can we identify donors in whom LVH is accompanied
y significant diastolic dysfunction and is less likely to
egress, which can affect the outcome detrimentally? Among
hose with LVH, it is known that healthy, young athletes
ay have physiologic hypertrophy with normal systolic and
iastolic LV function (22). These hearts are different from
earts of older donors with severe LVH, with long-standing
TN with impaired diastolic and even systolic function.
ecently, echocardiographic techniques such as tissue
oppler imaging, strain, and strain rate have been intro-
uced for comprehensive LV function assessment. Use of
hese new techniques should be evaluated in HTx in the
uture and may be extremely useful for transplant decision
aking in donors with moderate-to-severe LVH.
tudy limitations. The major limitation of our study is its
etrospective nature. However, this study includes the larg-
st number of patients who have received allografts with
VH. Moreover, this is the first study that used precise
easurements of LV thickness. Another limitation is the
ack of calculation of LV mass. The formula for LV mass
alculation requires cubing of several primary measurements
11). In a retrospective study where not all measurements
re made by a single operator, even small errors in these
easurements can be magnified; therefore, only primary
easurements were included.
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Heart Transplantation of Donors With LVH March 25, 2008:1214–20onclusions
ecipients of transplanted donor hearts with LVH had
imilar short- or long-term survivals to those who received
onor hearts without LVH. These results suggest that
onor hearts with mild and moderate LVH can be safely
sed for heart transplantation and may increase the number
f hearts available for transplantation. The lack of progres-
ion or even regression of LVH can be achieved in recipients
f donor hearts with LVH by optimal blood pressure
ontrol and treatment using drugs that have shown a
eneficial effect on LV remodeling.
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